Showing 4140 results for "als"

Collaboration to study PrimeC’s impacts on ALS disease mechanisms

NeuroSense Therapeutics has joined researchers at Massachusetts General Hospital to study the impact of its investigational therapy PrimeC on key amyotrophic lateral sclerosis (ALS) processes. The collaboration will the headed by Ghazaleh Sadri-Vakili, director of the Neuroepigenetics laboratory at the MassGeneral Institute for Neurodegenerative Disease. Using a new…

Exservan (riluzole oral film) for ALS

Exservan (riluzole oral film) is an approved oral treatment for amyotrophic lateral sclerosis (ALS). The medication can increase survival without the need for a tracheostomy — a tube inserted through the neck into the windpipe to help with breathing.

Tiglutik for ALS

Tiglutik (riluzole oral suspension) is a liquid formulation of riluzole approved for treating amyotrophic lateral sclerosis (ALS). The medication can slow disease progression, extending survival time or the need for a tracheostomy, which is when a breathing tube is inserted through the neck into the trachea.

Rilutek (riluzole) for ALS

Rilutek (riluzole) is an oral treatment approved to slow the progression of amyotrophic lateral sclerosis (ALS). The therapy can extend survival and/or the time to a tracheostomy — a procedure wherein a tube is inserted through the neck into the windpipe to help with breathing.